The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Lexeo Therapeutics Inc (NASDAQ: LXEO) was $9.51 for the day, up 0.74% from the previous closing price of $9.44. In other words, the price has increased by $0.74 from its previous closing price. On the day, 0.88 million shares were traded. LXEO stock price reached its highest trading level at $9.52 during the session, while it also had its lowest trading level at $9.17.
Ratios:
Our analysis of LXEO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.40 and its Current Ratio is at 7.40. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Raymond James on December 18, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $25.
On November 20, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $19.
On October 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $30.Guggenheim initiated its Buy rating on October 15, 2025, with a $30 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 18 ’25 when Townsend Richard Nolan sold 1,127 shares for $9.27 per share. The transaction valued at 10,447 led to the insider holds 240,991 shares of the business.
Adler Eric sold 615 shares of LXEO for $5,701 on Nov 18 ’25. The Chief Medical Officer now owns 72,646 shares after completing the transaction at $9.27 per share. On Nov 18 ’25, another insider, See Tai Sandi, who serves as the Chief Development Officer of the company, sold 386 shares for $9.27 each. As a result, the insider received 3,578 and left with 65,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 694109504 and an Enterprise Value of 579802496.
Stock Price History:
The Beta on a monthly basis for LXEO is 1.79, which has changed by 0.3841642 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $10.99, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 0.66%, while the 200-Day Moving Average is calculated to be 64.98%.
Shares Statistics:
LXEO traded an average of 1.47M shares per day over the past three months and 1848270 shares per day over the past ten days. A total of 72.99M shares are outstanding, with a floating share count of 60.28M. Insiders hold about 17.40% of the company’s shares, while institutions hold 77.32% stake in the company. Shares short for LXEO as of 1765756800 were 7101931 with a Short Ratio of 4.83, compared to 1763078400 on 5636938. Therefore, it implies a Short% of Shares Outstanding of 7101931 and a Short% of Float of 10.3999995.
Earnings Estimates
The market rating for Lexeo Therapeutics Inc (LXEO) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.68 and -$2.26 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.47, with 9.0 analysts recommending between -$1.03 and -$2.36.
